iShares Genomics Immunology and Healthcare ETF (IDNACL)
XSGO 
Summary
IDNACL Chart
IDNA: The Cutting Edge Of Medical Science Is A Risky Investment
The iShares Genomics Immunology and Healthcare ETF is invested in 49 companies involved in genomics, immunology and bioengineering. Compared with the biotechnology benchmark IBB, IDNA has value characteristics, but has greatly underperformed, losing over 20% since its inception. Among genomics-focused ETFs, PBE offers a relatively safer choice with better performance and lower volatility.
iShares Genomics Immunology and Healthcare ETF (IDNACL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has iShares Genomics Immunology and Healthcare ETF ever had a stock split?
iShares Genomics Immunology and Healthcare ETF Profile
| XSGO Exchange | US Country |
Overview
The fund is designed to cater to investors looking to capitalize on the advancement and long-term growth potential in the fields of genomics, immunology, and bioengineering. It stands out by committing at least 80% of its assets to securities that directly make up the index it tracks, ensuring that the investment is closely aligned with the market movements of companies operating within these innovative sectors. Moreover, the flexibility to invest up to 20% of its assets in derivatives, cash, and cash equivalents allows for strategic maneuvering to hedge against market volatility, optimize returns, and manage liquidity effectively. The underlying index includes a blend of both developed and emerging market companies, offering investors exposure to a global opportunity set within the burgeoning fields of genomics and bioengineering.
Products and Services
The fund offers investment products that are structured to provide investors with exposure to cutting-edge technology and medical advancements, specifically in:
- Component Securities of the Index:
These are the core investments of the fund, constituting at least 80% of its assets. By investing in the component securities of the index, the fund offers direct exposure to companies poised for growth within genomics, immunology, and bioengineering sectors. This aligns the fund’s performance closely with the innovation-driven market dynamics in these areas.
- Futures, Options, and Swap Contracts:
Up to 20% of the fund’s assets may be allocated to futures, options, and swap contracts. This allocation strategy aims to enhance the fund’s returns, provide flexibility in portfolio management, and potentially hedge against the risk inherent in the highly volatile sectors of genomics and bioengineering. These financial instruments allow the fund to capitalize on market predictions and safeguard against downturns.
- Cash and Cash Equivalents:
Part of the fund’s strategy includes investment in cash and cash equivalents, up to 20% of its assets. This not only serves as a risk management tool, allowing the fund to respond swiftly to market changes, but also ensures that liquidity is maintained. Having a portion of the portfolio in highly liquid assets enables the fund to seize investment opportunities as they arise and meet redemption requests without significant impact to the portfolio's overall strategy.
